Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1678
Shown on this page
12
Current sort
Recently updated
Campus scope
Memorial Sloan Kettering Cancer Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Memorial Sloan Kettering Cancer Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 493–504 of 1,678 matching trials with a site at Memorial Sloan Kettering Cancer Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief

NCT05877521
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Pain, Cancer Pain
Interventions
MORE treatments, Standard of Care for Pain Management
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 1 Interventional

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758
Status at this site: Recruiting
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, AB248
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 90 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Gilbert, Arizona • Los Angeles, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
33
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT07336472
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IBI3003
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
Site status not listed — check the official record
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 1 Interventional

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

NCT07612189
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions
NEOK002, NEOK002 RDE
Drug
Lead sponsor
NEOK Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

NCT05587517
Site status not listed — check the official record
View directory record Official record
Conditions
Grief, Trauma, Psychotherapy, Critical Care
Interventions
EMPOWER, Supportive Conversation
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Recruiting Phase 4 Interventional

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed/ Refractory Multiple Myeloma
Interventions
Talquetamab, Teclistamab, PD-1 Inhibitor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Denver, Colorado • New York, New York • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 6:36 AM EDT

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Memorial Sloan Kettering Cancer Center at any site, browse by condition, or browse by U.S. city.